Multiplying the export of Antibiotice Iași nine times in the last 20 years. We build the future together with our partners!
These days, Antibiotice Iași is present for the 20th consecutive year, at the most important exhibition event of the world pharmaceutical industry, CPHI Worldwide, which is held in Barcelona, Spain.
This far-reaching event is the main driver of the development of international business which, over time, has multiplied several times, the company estimating that they will reach the value of 215 million lei at the end of this year, which represents 36% from the turnover.
“In the last 20 years, we have consolidated partnerships with large companies from all over the world and we are here, at this international fair, to convey to them that in a divided world, in a world where we seem to no longer find each other, we are capable let’s build a future together with our partners”, said Ioan NANI, Antibiotice general manager.
The Antibiotice team at CPHI Worldwide, made up of specialists in the fields of research and development, portfolio management, import, export, business development, marketing and sales has over 150 meetings with business partners from all over the world, in order to identify new business opportunities and of expansion in the global market by leveraging the company’s research capabilities and production infrastructure.
By participating in such international events, Antibiotice sends a message of stability and continuity to its partners, alongside which it aims to double foreign business by 2030, in line with the strategic development plan “The Future Together”.
CPHI 2023
At the end of 2022, Antibiotice inaugurated the most modern topical medicine factory in Europe, with an investment of 20 million euros, thus consolidating its position as a national leader in the manufacture of topical pharmaceutical products. With a 50% higher capacity compared to the previous one and in compliance with the highest production and quality standards, this investment offers the company greater openness to international markets characterized by a high degree of competitiveness and innovation.
Also, in May 2023, Antibiotice obtained the agreement for non-refundable funds in the amount of over 85 million lei for a production capacity of sterile products, solutions and topicals.
CPHI Worldwide
The new production capacities, together with the attraction of 100 new products until the horizon of 2030, are an integral part of the company’s strategic development plan “The Future Together”, which plans to double turnover, profit, and increase market shares both locally as well as internationally.
The continuity of the 20-year presence at CPHI Worldwide represents, consequently, a premise for the expansion and consolidation of Antibiotice on foreign markets alongside its partners, the company being the most important Romanian manufacturer of generic drugs with international recognition that exports to 70 countries from worldwide.
